Encouraged by the scientific reports related to PTs exerting marked antitumor action through different mechanisms (e.g., EGFR signaling) [19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37], in vitro and in silico assays were conducted to determine their potency as EGFR-targeted anti-glioma agents. This evidence concerns the gene EGFR and glioma.